Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 381 clinical trials
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination therapy of …

bladder tumor
carboplatin
atezolizumab
carcinoma
  • 0 views
  • 11 Jul, 2022
  • 2 locations
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

atezolizumab
cancer
invasive bladder cancer
transurethral resection
carcinoma
  • 0 views
  • 07 Oct, 2022
  • 5 locations
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy (TOMBOLA)

Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer. However, response rates are low and no biomarkers have yet shown

metastatic bladder carcinoma
atezolizumab
cancer
carcinoma
bladder tumor
  • 0 views
  • 04 Oct, 2022
  • 5 locations
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Current treatment of localized muscle-invasive bladder cancer is still associated with high relapse and death rate as well as the need for complete bladder resection or irradiation. The

intravesical bcg
atezolizumab
invasive bladder cancer
EGFR
carcinoma
  • 0 views
  • 04 Oct, 2022
  • 9 locations
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy (BladderSpar)

Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient's refusal. This study is designed as a

atezolizumab
cancer
invasive bladder cancer
bladder tumor
metastasis
  • 0 views
  • 04 Oct, 2022
  • 12 locations
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy

corticosteroids
monoclonal antibody therapy
autoimmune disease
cystoscopy
atezolizumab
  • 42 views
  • 21 Oct, 2022
  • 179 locations
Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)

This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called atezolizumab vs. atezolizumab alone in treating patients with urothelial cancer that has spread to other places in the body (metastatic). The addition of radiation to immunotherapy may shrink the cancer, but it could also …

  • 1 views
  • 28 Oct, 2022
  • 38 locations
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

The purpose of this study is to test the safety and effectiveness of immunotherapy (checkpoint inhibitor therapy) in advanced bladder cancer when given intermittently. An unanswered question

pembrolizumab
atezolizumab
cancer
nivolumab
avelumab
  • 0 views
  • 16 Jun, 2022
  • 1 location
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (inoperable), or has spread to other places in the body (metastatic). …

  • 4 views
  • 20 Oct, 2022
  • 6 locations
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after progression on PD-1 or PD-L1 targeted antibodies. Plinabulin blocks tumor growth by targeting both …

  • 0 views
  • 04 Oct, 2022
  • 1 location